BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11585270)

  • 1. Gender discrepancy observed between chemotherapy-induced emesis and hiccups.
    Liaw CC; Wang CH; Chang HK; Liau CT; Yeh KY; Huang JS; Lin YC
    Support Care Cancer; 2001 Sep; 9(6):435-41. PubMed ID: 11585270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-related hiccups: male predominance, induction by dexamethasone, and protection against nausea and vomiting.
    Liaw CC; Wang CH; Chang HK; Wang HM; Huang JS; Lin YC; Chen JS
    J Pain Symptom Manage; 2005 Oct; 30(4):359-66. PubMed ID: 16256900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
    Chen PT; Liaw CC
    Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron.
    Liaw CC; Wang CH; Chang HK; Kao CY; Huang JS
    Am J Clin Oncol; 2000 Jun; 23(3):253-7. PubMed ID: 10857888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
    Liaw CC; Chang HK; Liau CT; Huang JS; Lin YC; Chen JS
    Am J Clin Oncol; 2003 Feb; 26(1):12-5. PubMed ID: 12576917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
    Liaw CC; Wang CH; Chang HK; Kao CY; Huang JS
    Chang Gung Med J; 2000 Jul; 23(7):413-9. PubMed ID: 10974756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
    Roila F; Rolski J; Ramlau R; Dediu M; Russo MW; Bandekar RR; Grunberg SM
    Ann Oncol; 2009 Nov; 20(11):1867-73. PubMed ID: 19541792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
    Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
    Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
    Krzakowski M; Graham E; Goedhals L; Joly F; Pawlicki M; Rapoport B; Yelle L; Lees J; McQuade B
    Anticancer Drugs; 1998 Aug; 9(7):593-8. PubMed ID: 9773802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.